THRB and metabolic dysfunction-associated steatohepatitis: This oral thyroid hormone receptor beta (THR-β) agonist is administered once daily and selectively targets THR-β in the liver, addressing the underlying causes of MASH by mediating metabolic processes such as reducing lipid levels while avoiding the activation of THR-α, thereby alleviating associated safety concerns.